Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05338775 · ClinicalTrials.gov registry record · Phase 1
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
- 19
- Study locations
NCT05338775: Active Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by Janssen Research & Development.
NCT05338775 is a Phase 1 study of Relapsed/Refractory Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 74 participants, below the 167-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (56% lower). The trial reports 19 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05338775, a Phase 1 study of Relapsed/Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Primary Outcome
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Talquetamab
- DRUG PD-1 Inhibitor
Study Locations (19)
Other
- CHU de Montpellier Hopital Saint Eloi - Montpellier
- CHU de Nantes hotel Dieu - Nantes
- CHU Poitiers - Hopital la Miletrie - Poitiers
- Institut Universitaire du Cancer Toulouse Oncopole - Toulouse
- Universitatsklinikum Carl Gustav Carus Dresden - Dresden
- Universitaetsklinikum Hamburg Eppendorf - Hamburg
- Universitaetsklinikum Heidelberg - Heidelberg
- Universitatsklinikum Wurzburg - Würzburg
- Hosp. Univ. Germans Trias I Pujol - Badalona
- Hosp Univ Fund Jimenez Diaz - Madrid
- Clinica Univ. de Navarra - Pamplona
- Hosp Clinico Univ de Salamanca - Salamanca
New York
- The Blavatnik Family Chelsea Medical Center at Mount Sinai - New York
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
- Vanderbilt Ingram Cancer Center - Nashville
Colorado
- Colorado Blood Cancer Institute - Denver
North Carolina
- Wake Forest Baptist Medical Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2027-05-03 |
| Phase | Phase 1 |
What the registry record for NCT05338775 still lists
NCT05338775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 167-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Teclistamab is the first listed.
NCT05338775 lists 19 locations in 5 states (Other, New York, Tennessee).
Frequently Asked Questions
What is clinical trial NCT05338775 about?
NCT05338775 is a clinical study titled "A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma". The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
What is the current status of trial NCT05338775?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2022-05-25. Estimated completion is 2027-05-03.
What conditions does trial NCT05338775 study?
This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT05338775?
The interventions under investigation include: Teclistamab (DRUG), Talquetamab (DRUG), PD-1 Inhibitor (DRUG).
Who is sponsoring clinical trial NCT05338775?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05338775 being conducted?
This trial has 19 study locations across Colorado, New York, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05338775's enrollment target sits among peer trials
74 11th of 14 higher than 4 of 14 other Relapsed/Refractory Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsed/Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RECRUITING · Phase 1
-
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI